These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 13679640)

  • 1. Preparation of peptide-loaded dendritic cells for cancer immunotherapy.
    Morse MA; Clay T; Colling K; Lyerly HK
    Mol Biotechnol; 2003 Sep; 25(1):95-9. PubMed ID: 13679640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
    Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
    J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy.
    Morse MA; Zhou LJ; Tedder TF; Lyerly HK; Smith C
    Ann Surg; 1997 Jul; 226(1):6-16. PubMed ID: 9242332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.
    Morse MA; Deng Y; Coleman D; Hull S; Kitrell-Fisher E; Nair S; Schlom J; Ryback ME; Lyerly HK
    Clin Cancer Res; 1999 Jun; 5(6):1331-8. PubMed ID: 10389916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen.
    Itoh T; Ueda Y; Kawashima I; Nukaya I; Fujiwara H; Fuji N; Yamashita T; Yoshimura T; Okugawa K; Iwasaki T; Ideno M; Takesako K; Mitsuhashi M; Orita K; Yamagishi H
    Cancer Immunol Immunother; 2002 Apr; 51(2):99-106. PubMed ID: 11904734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells.
    Alters SE; Gadea JR; Philip R
    Adv Exp Med Biol; 1997; 417():519-24. PubMed ID: 9286413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides.
    Liu KJ; Wang CC; Chen LT; Cheng AL; Lin DT; Wu YC; Yu WL; Hung YM; Yang HY; Juang SH; Whang-Peng J
    Clin Cancer Res; 2004 Apr; 10(8):2645-51. PubMed ID: 15102666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy.
    Ueda Y; Itoh T; Fuji N; Harada S; Fujiki H; Shimizu K; Shiozaki A; Iwamoto A; Shimizu T; Mazda O; Kimura T; Sonoda Y; Taniwaki M; Yamagishi H
    Cancer Immunol Immunother; 2007 Mar; 56(3):381-9. PubMed ID: 16830156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of dendritic cells from adherent cells of cord blood by culture with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha.
    Zheng Z; Takahashi M; Narita M; Toba K; Liu A; Furukawa T; Koike T; Aizawa Y
    J Hematother Stem Cell Res; 2000 Aug; 9(4):453-64. PubMed ID: 10982243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of immature autologous clinical grade dendritic cells for vaccination of cancer patients.
    Toungouz M; Quinet C; Thille E; Fourez S; Pradier O; Delville JP; Velu T; Lambermont M
    Cytotherapy; 1999; 1(6):447-53. PubMed ID: 20426545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
    Babatz J; Röllig C; Löbel B; Folprecht G; Haack M; Günther H; Köhne CH; Ehninger G; Schmitz M; Bornhäuser M
    Cancer Immunol Immunother; 2006 Mar; 55(3):268-76. PubMed ID: 16034561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56(high+) Interferon-α-induced dendritic cells.
    Nieda M; Terunuma H; Eiraku Y; Deng X; Nicol AJ
    Exp Dermatol; 2015 Jan; 24(1):35-41. PubMed ID: 25363560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
    Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T
    Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
    Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
    Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonviral transfection of human umbilical cord blood dendritic cells is feasible, but the yield of dendritic cells with transgene expression limits the application of this method in cancer immunotherapy.
    Markowicz S; Niedzielska J; Kruszewski M; Ołdak T; Gajkowska A; Machaj EK; Skurzak H; Pojda Z
    Acta Biochim Pol; 2006; 53(1):203-12. PubMed ID: 16404477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.
    Brossart P; Zobywalski A; Grünebach F; Behnke L; Stuhler G; Reichardt VL; Kanz L; Brugger W
    Cancer Res; 2000 Aug; 60(16):4485-92. PubMed ID: 10969796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.